Human Albumin Csl Behring

Human Albumin Csl Behring is a sterile solution for injection that contains human plasma protein (human albumin) as its active ingredient; the product’s strength is not specified in the available data. It is manufactured in the European Union and supplied by CSL Behring. The preparation is intended for intravenous administration under medical supervision and is classified as a prescription‑only plasma protein used to support circulatory volume.

Human Albumin Csl Behring is employed in clinical settings to address conditions associated with reduced plasma oncotic pressure or intravascular volume loss. It is administered intravenously when rapid plasma expansion is required. - Treatment of hypovolemia resulting from hemorrhage, trauma, or surgery. - Management of hypoalbuminemia in patients with liver cirrhosis or nephrotic syndrome. - Volume support for extensive burn injuries to maintain tissue perfusion. - Adjunct therapy in septic or cardiogenic shock to improve hemodynamics. - Replacement therapy during plasma exchange or therapeutic apheresis procedures.

Adverse reactions to Human Albumin Csl Behring are generally infrequent but may occur following intravenous infusion; monitoring during and after administration is recommended to identify any response promptly.

Common: - Transient fever or chills that develop during or shortly after the infusion. - Mild urticaria or localized skin erythema occurring at the infusion site. - Headache or dizziness without accompanying hemodynamic instability. - Nausea, vomiting, or mild abdominal discomfort that resolves spontaneously.

Serious: - Acute anaphylactic or anaphylactoid reaction presenting with respiratory distress, hypotension, and possible loss of consciousness. - Volume overload that may progress to pulmonary edema, reduced oxygenation, or exacerbation of congestive heart failure. - Hemolysis or severe thrombocytopenia manifesting as sudden drop in hemoglobin or platelet count. - Potential transmission of infectious agents despite rigorous donor screening and viral inactivation procedures.

When using Human Albumin Csl Behring, clinicians should observe specific precautions to minimize risk and ensure appropriate patient selection. - Assess volume status and cardiac function before infusion. - Use caution in patients with renal or hepatic impairment. - Avoid rapid infusion rates; administer over recommended time. - Monitor for signs of fluid overload during and after administration. - Consider risk of allergic reactions in individuals with known albumin sensitivity. - Evaluate for potential infection transmission in immunocompromised patients. - Document lot number and infusion details for traceability.

Human Albumin Csl Behring may interact with other intravenously administered agents; awareness of potential interactions helps guide safe co‑administration. Avoid: - Concomitant use with high‑dose diuretics that may precipitate intravascular volume depletion. - Simultaneous infusion with other plasma expanders that could cause excessive oncotic load. Use with caution: - Vasopressor agents, as rapid volume expansion may augment their hemodynamic effects. - Blood products (e.g., packed red cells) administered through the same line, requiring line flushing to prevent incompatibility. - Renal replacement therapies, where altered fluid balance may affect albumin distribution. - Anticoagulants, because changes in plasma protein levels can modify drug binding.